Research.Patient.info

Focal segmental glomerulosclerosis (FSGS) research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)
Germany · Belgium · France